178 related articles for article (PubMed ID: 16177194)
1. Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice.
Tangpricha V; Spina C; Yao M; Chen TC; Wolfe MM; Holick MF
J Nutr; 2005 Oct; 135(10):2350-4. PubMed ID: 16177194
[TBL] [Abstract][Full Text] [Related]
2. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse.
Masuda S; Byford V; Arabian A; Sakai Y; Demay MB; St-Arnaud R; Jones G
Endocrinology; 2005 Feb; 146(2):825-34. PubMed ID: 15498883
[TBL] [Abstract][Full Text] [Related]
3. Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.
Chow EC; Quach HP; Vieth R; Pang KS
Am J Physiol Endocrinol Metab; 2013 May; 304(9):E977-89. PubMed ID: 23482451
[TBL] [Abstract][Full Text] [Related]
4. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5.
Mehta RG; Moriarty RM; Mehta RR; Penmasta R; Lazzaro G; Constantinou A; Guo L
J Natl Cancer Inst; 1997 Feb; 89(3):212-8. PubMed ID: 9017001
[TBL] [Abstract][Full Text] [Related]
5. Clonal differences in expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3).
Bareis P; Kállay E; Bischof MG; Bises G; Hofer H; Pötzi C; Manhardt T; Bland R; Cross HS
Exp Cell Res; 2002 Jun; 276(2):320-7. PubMed ID: 12027461
[TBL] [Abstract][Full Text] [Related]
6. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
Chen TC; Holick MF; Lokeshwar BL; Burnstein KL; Schwartz GG
Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
[TBL] [Abstract][Full Text] [Related]
8. Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3.
Kemmis CM; Salvador SM; Smith KM; Welsh J
J Nutr; 2006 Apr; 136(4):887-92. PubMed ID: 16549446
[TBL] [Abstract][Full Text] [Related]
9. 1α,24(S)(OH)2D2 normalizes bone morphology and serum parathyroid hormone without hypercalcemia in 25-hydroxyvitamin D-1-hydroxylase (CYP27B1)-deficient mice, an animal model of vitamin D deficiency with secondary hyperparathyroidism.
St-Arnaud R; Arabian A; Yu VW; Akhouayri O; Knutson JC; Strugnell SA
J Endocrinol Invest; 2008 Aug; 31(8):711-7. PubMed ID: 18852532
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the murine renal vitamin D receptor by 1,25-dihydroxyvitamin D3 and calcium.
Healy KD; Zella JB; Prahl JM; DeLuca HF
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9733-7. PubMed ID: 12900504
[TBL] [Abstract][Full Text] [Related]
11. 25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer.
de Lyra EC; da Silva IA; Katayama ML; Brentani MM; Nonogaki S; Góes JC; Folgueira MA
J Steroid Biochem Mol Biol; 2006 Aug; 100(4-5):184-92. PubMed ID: 16828283
[TBL] [Abstract][Full Text] [Related]
12. 25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression.
Bareis P; Bises G; Bischof MG; Cross HS; Peterlik M
Biochem Biophys Res Commun; 2001 Jul; 285(4):1012-7. PubMed ID: 11467853
[TBL] [Abstract][Full Text] [Related]
13. Antenatal endotoxin disrupts lung vitamin D receptor and 25-hydroxyvitamin D 1α-hydroxylase expression in the developing rat.
Mandell E; Seedorf GJ; Ryan S; Gien J; Cramer SD; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2015 Nov; 309(9):L1018-26. PubMed ID: 26342089
[TBL] [Abstract][Full Text] [Related]
14. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
Ly LH; Zhao XY; Holloway L; Feldman D
Endocrinology; 1999 May; 140(5):2071-6. PubMed ID: 10218956
[TBL] [Abstract][Full Text] [Related]
15. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells.
Reichrath J; Rech M; Moeini M; Meese E; Tilgen W; Seifert M
Cancer Biol Ther; 2007 Jan; 6(1):48-55. PubMed ID: 17172823
[TBL] [Abstract][Full Text] [Related]
16. Analysis of 25-hydroxyvitamin D3-1alpha-hydroxylase in normal and malignant breast tissue.
Friedrich M; Diesing D; Cordes T; Fischer D; Becker S; Chen TC; Flanagan JN; Tangpricha V; Gherson I; Holick MF; Reichrath J
Anticancer Res; 2006; 26(4A):2615-20. PubMed ID: 16886671
[TBL] [Abstract][Full Text] [Related]
17. Dietary vitamin D₃ and 1,25-dihydroxyvitamin D₃ (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer.
Swami S; Krishnan AV; Wang JY; Jensen K; Horst R; Albertelli MA; Feldman D
Endocrinology; 2012 Jun; 153(6):2576-87. PubMed ID: 22454149
[TBL] [Abstract][Full Text] [Related]
18. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
19. 1α,25-dihydroxyvitamin D3 modulates CYP2R1 gene expression in human oral squamous cell carcinoma tumor cells.
Sundaram K; Sambandam Y; Tsuruga E; Wagner CL; Reddy SV
Horm Cancer; 2014 Apr; 5(2):90-7. PubMed ID: 24497297
[TBL] [Abstract][Full Text] [Related]
20. Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro.
Seifert M; Rech M; Meineke V; Tilgen W; Reichrath J
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):375-9. PubMed ID: 15225804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
